BAN2401
Selected indexed studies
- Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. (Expert Opin Investig Drugs, 2023) [PMID:36749830]
- Lecanemab in Early Alzheimer's Disease. (N Engl J Med, 2023) [PMID:36449413]
- The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. (J Alzheimers Dis, 2015) [PMID:25096615]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The Black Book of Psychotropic Dosing and Monitoring. (2024) pubmed
- Lecanemab in Early Alzheimer's Disease. (2023) pubmed
- Lecanemab: Appropriate Use Recommendations. (2023) pubmed
- Updated safety results from phase 3 lecanemab study in early Alzheimer's disease. (2024) pubmed
- Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. (2023) pubmed
- A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. (2021) pubmed
- The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. (2015) pubmed
- Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. (2016) pubmed
- Alzheimer's disease: From immunotherapy to immunoprevention. (2023) pubmed
- Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. (2024) pubmed